linkedin
We’re excited to be part of this year’s AGE Congress. Endoscopic gynaecology is evolving at a rapid pace, and this event is the perfect opportunity to stay up to date with the latest developments.
The results speak for themselves:
• 90.2% reduction in fibroid volume within 12–36 months [1]
• >84.9% decrease in symptom severity after just one month [2]
• 98.04% patient satisfaction rate [3]
With our radiofrequency ablation portfolio for uterine fibroids, we are proud to present the latest generation of the VIVA RF System by STARMED.
🎯 Visit us at our booth on site. We look forward to meeting you in person and exploring potential business opportunities together.
You can find more information about the VIVA RF Generator here: https://www.inomed.com/products-ablation-viva-rf-system/
#inomed#radiofrequencyablation#uterus#uterinefibroid#gynaecology#surgery#vivarfgenerator#starmed#monitoring#ionm#iom#agecongress#medicaltechnology#RFA#uterinehealth
_________________________
[1] Fasciani, A., Turtulici, G., Pedullà, A., & Sirito, R. (2023). Uterine Myoma Position-based Radiofrequency Ablation (UMP-b RFA): 36 months follow-up clinical outcomes. European journal of obstetrics, gynecology, and reproductive biology, 281, 23–28. https://doi.org/10.1016/j.ejogrb.2022.12.006
[2] Fasciani, A., Turtulici, G., Siri, G., Ferrero, S., & Sirito, R. (2020). A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas. Medicina (Kaunas, Lithuania),56(3),122. https://doi.org/10.3390/medicina56030122
[3] Rey, V. E., Labrador, R., Falcon, M., & Garcia-Benitez, J. L. (2019). Transvaginal Radiofrequency Ablation of Myomas: Technique, Outcomes, and Complications. Journal of laparoendoscopic & advanced surgical techniques. Part A, 29(1),24–28. https://doi.org/10.1089/lap.2018.0293
